ESMO 2025 – bemarituzumab fails to convince
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
